Invizyne Technologies Selected for $2 Million Project to Advance Sustainable Aviation Fuel Capabilities
Invizyne Technologies (NASDAQ: IZTC) has been awarded a $2 million project from the U.S. Department of Defense's BioMADE initiative to advance sustainable aviation fuel (SAF) capabilities. The project, in partnership with the University of Georgia, focuses on enabling enzyme production for cell-free biomanufacturing of isobutanol, a key SAF precursor. This follows previous grants totaling $5.85 million from the Department of Energy. The project aims to develop an enzyme production pipeline and deploy technology in 100L pilot-scale facilities. The global SAF market is projected to grow at 52.2% annually, reaching $27.4 billion by 2032.
Invizyne Technologies (NASDAQ: IZTC) ha ricevuto un progetto da 2 milioni di dollari dall'iniziativa BioMADE del Dipartimento della Difesa degli Stati Uniti per avanzare le capacità del carburante sostenibile per l'aviazione (SAF). Il progetto, in collaborazione con l'Università della Georgia, si concentra sull'abilitazione della produzione di enzimi per la biomanifattura senza cellule dell'isobutanolo, un precursore chiave del SAF. Questo segue precedenti sovvenzioni che ammontano a 5,85 milioni di dollari da parte del Dipartimento dell'Energia. Il progetto mira a sviluppare una pipeline di produzione di enzimi e a implementare la tecnologia in impianti pilota su scala di 100 litri. Si prevede che il mercato globale del SAF cresca del 52,2% all'anno, raggiungendo 27,4 miliardi di dollari entro il 2032.
Invizyne Technologies (NASDAQ: IZTC) ha recibido un proyecto de 2 millones de dólares de la iniciativa BioMADE del Departamento de Defensa de los EE. UU. para avanzar en las capacidades de combustible de aviación sostenible (SAF). El proyecto, en colaboración con la Universidad de Georgia, se centra en la producción de enzimas para la biomanufactura sin células del isobutanol, un precursor clave del SAF. Esto sigue a subvenciones anteriores que totalizan 5,85 millones de dólares por parte del Departamento de Energía. El proyecto tiene como objetivo desarrollar una cadena de producción de enzimas y desplegar tecnología en instalaciones piloto de 100 litros. Se proyecta que el mercado global de SAF crecerá un 52,2% anualmente, alcanzando 27,4 mil millones de dólares para 2032.
Invizyne Technologies (NASDAQ: IZTC)는 미국 국방부의 BioMADE 이니셔티브로부터 200만 달러의 프로젝트를 수여받아 지속 가능한 항공 연료(SAF) 기능을 증진하고 있습니다. 이 프로젝트는 조지아 대학교와의 협력으로 진행되며, SAF의 주요 전구체인 이소부탄올의 세포 없는 바이오제조를 위한 효소 생산을 가능하게 하는 데 중점을 두고 있습니다. 이는 에너지부로부터 총 585만 달러의 이전 보조금에 이은 것입니다. 이 프로젝트는 효소 생산 파이프라인을 개발하고 100L 파일럿 규모 시설에 기술을 배치하는 것을 목표로 하고 있습니다. 전 세계 SAF 시장은 매년 52.2% 성장할 것으로 예상되며, 2032년까지 274억 달러에 이를 것으로 보입니다.
Invizyne Technologies (NASDAQ: IZTC) a reçu un projet de 2 millions de dollars de l'initiative BioMADE du Département de la Défense des États-Unis pour faire progresser les capacités de carburant d'aviation durable (SAF). Le projet, en partenariat avec l'Université de Géorgie, se concentre sur la production d'enzymes pour la biomanufacture sans cellules de l'isobutanol, un précurseur clé du SAF. Cela fait suite à des subventions précédentes d'un montant total de 5,85 millions de dollars du Département de l'Énergie. Le projet vise à développer un pipeline de production d'enzymes et à déployer une technologie dans des installations pilotes de 100 litres. Le marché mondial du SAF devrait croître de 52,2 % par an, atteignant 27,4 milliards de dollars d'ici 2032.
Invizyne Technologies (NASDAQ: IZTC) hat ein 2 Millionen Dollar Projekt von der BioMADE-Initiative des US-Verteidigungsministeriums erhalten, um die Fähigkeiten von nachhaltigem Flugtreibstoff (SAF) voranzutreiben. Das Projekt, in Zusammenarbeit mit der University of Georgia, konzentriert sich auf die Ermöglichung der Enzymproduktion für die zellfreie Bioproduktion von Isobutanol, einem wichtigen SAF-Vorläufer. Dies folgt auf frühere Zuschüsse in Höhe von insgesamt 5,85 Millionen Dollar vom Energieministerium. Das Projekt zielt darauf ab, eine Enzymproduktionspipeline zu entwickeln und Technologie in 100L-Pilotanlagen einzusetzen. Der globale SAF-Markt wird voraussichtlich jährlich um 52,2 % wachsen und soll bis 2032 27,4 Milliarden Dollar erreichen.
- Secured $2 million BioMADE grant for SAF development
- Previously obtained $5.85 million in DOE grants
- Targeting fast-growing SAF market projected to reach $27.4B by 2032
- Advancing to 100L pilot-scale facilities
- None.
Insights
The
The cell-free enzyme approach for isobutanol production represents a significant technological breakthrough in biomanufacturing. The technology's ability to convert renewable sugars into isobutanol at scale could revolutionize SAF production, offering a more efficient alternative to traditional fermentation methods. The partnership with the University of Georgia and DOD backing validates the technology's potential. The broader application potential across various industrial processes suggests this platform technology could disrupt multiple sectors beyond aviation fuel, particularly in areas requiring sustainable chemical production. The focus on enzyme production and processing pipeline development addresses a critical scaling challenge in biomanufacturing.
Project is part of the U.S. Department of Defense’s BioMADE initiative to support U.S. bioindustrial manufacturing innovations and workforce development
Monrovia, CA, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Today, Invizyne Technologies, Inc., (NASDAQ: IZTC) ("Invizyne"), a leading designer of cell-free, enzyme-based biomanufacturing systems to produce commercially important molecules and chemicals for everyday life, announced it was awarded a
The project is a cost share grant from the U.S. Department of Defense’s BioMADE initiative, in partnership with the University of Georgia. It is one of 17 BioMADE projects announced on October 30, 2024, to drive the scale-up and commercialization of American biomanufactured products.
“The next five to ten years will determine the global leader of the bioeconomy. At BioMADE, we believe the U.S. is uniquely positioned to seize this opportunity,” said Dr. Douglas Friedman, Chief Executive Officer at BioMADE. “We are proud to support these member-driven projects that will translate our country’s rich history of biotechnology innovation into manufacturing leadership. All Americans will benefit from investments in America’s bioindustrial manufacturing future.”
Novel Cell-Free Approach to Address
Prior to the BioMADE grant, Invizyne was awarded a total of
Isobutanol is a commodity chemical that can replace conventional petroleum-based fuels like gasoline and serves as a precursor to SAF. The global SAF market is expected to grow at a compound annual rate of
Project Details
The latest grant from BioMADE will be used to take the next step toward cell-free biomanufacturing of isobutanol. Specifically, it will be used to develop an enzyme production and processing pipeline and deploy Invizyne’s technology in 100L pilot-scale facilities.
"This initiative could indeed mark the beginning of a new era in sustainable biofuel production, bringing us closer to a greener, more efficient future. That’s because at its heart, this project seeks to mature the Technology Readiness Level of our cell-free enzyme approach, enabling the project participants to convert renewable sugars into isobutanol at scale,” said Paul Opgenorth, PhD, Co-Founder & VP of Development at Invizyne.
Broader Vision and Impact
“While the BioMADE project will play a pivotal role in validating the technical and economic feasibility of cell-free isobutanol production, it’s also important to understand that our vision at Invizyne extends beyond biofuel applications,” said Michael Heltzen, CEO of Invizyne. “We see this project as establishing a framework for expanding Invizyne’s cell-free approach into various industrial processes, too. Now that we have completed our IPO and we are able to continue to mature our technology, I fully believe we can become the leader in next generation biomanufacturing and dramatically reduce greenhouse gas emissions and foster a shift toward renewable solutions in the process.”
About BioMADE
By supporting the scale-up of bioindustrial manufacturing technology from research labs to commercial production, BioMADE and its network of nearly 300 members across 37 states are strengthening American competitiveness, securing the U.S. supply chain, reshoring manufacturing jobs, supporting rural development and domestic agriculture, and producing more sustainable products untethered from reliance on petroleum. BioMADE is building a diverse and globally competitive STEM workforce, preparing American workers to fill new jobs throughout the U.S. bioindustrial manufacturing ecosystem, including BioMADE’s national infrastructure network of pilot-scale facilities. BioMADE was catalyzed by the U.S. Department of Defense and is a proud member of Manufacturing USA®. Read about the new projects below and learn more about BioMADE by visiting biomade.org
About Invizyne
Invizyne Technologies, Inc. is a cell-free enzyme-based biomanufacturing technology company headquartered in Monrovia, California. Invizyne is redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals, such as Active Pharmaceutical Ingredients (APIs), biofuels, food flavors, fragrances, cosmetics, etc. Management of Invizyne believes that its biomanufacturing platform, known as SimplePath™, will be a significant alternative to the current methods of chemical compound production, which are generally chemical synthesis, natural extraction, and synthetic biology. The objective for the SimplePath™ platform is to enable the efficient production of a diverse range of chemicals otherwise impossible to make, or very expensive to make. The SimplePath™ platform not only can maximize the value of these resources but also can contribute to the development of novel and renewable chemical compounds that hold the potential to open new markets and business opportunities.
For more information, please visit www.invizyne.com
Forward-Looking Statements
This press release contains "forward-looking statements." These forward-looking statements are made as of the date they were first issued and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Words such as “aim”, "expect," "anticipate," "should," "believe," "hope," "target," "project," "goals," "estimate," "potential," "predict," "may," "will," "might," "could," "intend," "shall" and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements.
Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond Invizyne's control. Invizyne's actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors. The forward-looking statements included in this press release represent Invizyne's views as of the date of this press release. Invizyne anticipates that subsequent events and developments will cause its views to change. Invizyne undertakes no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing Invizyne's views as of any date subsequent to the date of this press release.
Media contacts:
Lasse Görlitz, VP of Communications
(858) 319-7135
press@invizyne.com
Investor Relations Contact:
IR@invizyne.com
FAQ
What is the value of the BioMADE grant awarded to Invizyne Technologies (IZTC)?
What is the projected market size for Sustainable Aviation Fuel (SAF) that Invizyne (IZTC) is targeting?
What is the total grant funding received by Invizyne (IZTC) for isobutanol production?
What scale of facilities is Invizyne (IZTC) planning to deploy its technology?
